amg 890
Nucleic acidexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jul 30, 2018 (NCT03626662)
Timeline
Indications
Mechanism of action
- Apolipoprotein(a)ANTISENSE INHIBITOR
LPA antisense inhibitor
- LPA mRNARNAI INHIBITOR
LPA mRNA rnai inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650413 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07293260 | Phase 3 | Mar 21, 2026 | Amgen |
| NCT07136012 | Phase 3 | Aug 22, 2025 | Amgen |
| NCT06411860 | Phase 1 | Oct 10, 2024 | Amgen |
| NCT05581303 | Phase 3 | Dec 21, 2022 | Amgen |
| NCT05481411 | Phase 1 | Sep 13, 2022 | Amgen |
| NCT05489614 | Phase 1 | Sep 13, 2022 | Amgen |
| NCT04987320 | Phase 1 | Jul 28, 2021 | Amgen |
| NCT04270760 | Phase 2 | Jun 10, 2020 | Amgen |
| NCT03626662 | Phase 1 | Jul 30, 2018 | Amgen |
| NCT07079267 | N/A | — | Amgen |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 10 | 10 | 4 | 2018 |
1 organizations
Page 1 / 1